Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
Nicox Announces Results from the NCX 4251 Phase 2b Mississippi Blepharitis Trial

September 30, 2021

View Press Release Corporate presentation Contact us
Previous